Home / Health / FDA OKs New Hodgkin's Lymphoma Frontline Treatment
FDA OKs New Hodgkin's Lymphoma Frontline Treatment
20 Mar
Summary
- FDA approved a new combination treatment for Hodgkin's lymphoma.
- The therapy, Opdivo, is now a frontline option for advanced disease.
- Study showed improved progression-free survival versus competitor.
The U.S. Food and Drug Administration has granted approval for a new combination treatment aimed at patients aged 12 and older diagnosed with previously untreated stage III or IV classical Hodgkin's lymphoma. This therapy, marketed as Opdivo, is already recognized for its efficacy against several other advanced or metastatic cancers, including melanoma and lung cancer.
This newly authorized regimen combines Opdivo with a standard chemotherapy blend, doxorubicin, vinblastine, and dacarbazine (AVD). The approval signifies a crucial advancement, presenting a novel frontline therapeutic choice for individuals with advanced-stage Hodgkin's lymphoma, a cancer originating in white blood cells.
Data from a significant study involving 994 patients substantiated the approval, revealing that the Opdivo-based regimen substantially enhanced progression-free survival when contrasted with a treatment regimen utilizing brentuximab vedotin. Additionally, the FDA has converted some of Opdivo's prior accelerated approvals to traditional approvals for relapsed or refractory cases.
